You asked:
1. How many patients are currently (past 3 months) undergoing treatment for melanoma, and how many of these are BRAF+ ?
2. For patients currently (past 3 months) under treatment for melanoma
a. How many patients are Stage IIIa?
b. How many patients are Stage III resectable?
c. How many Stage III patients received a complete resection in the past 3 months?
3. In the past 3 months, how many melanoma patients were treated with the following:
a. Bevacizumab
b. Cobimetinib
c. Dabrafenib
d. Dabrafenib AND Trametinib
e. Dacarbazine
f. Encorafenib AND Binimetinib
g. Ipilimumab
h. Ipilimumab AND Nivolumab
i. Nivolumab
j. Pembrolizumab
k. Trametinib
l. Vemurafenib
m. Vemurafenib AND Cobimetinib
n. Other active systemic anti-cancer therapy
o. Palliative care only
4. In the past 3 months how many patients were treated with the following for breast cancer?
a. Abemaciclib + Anastrozole/Exemestane/Letrozole
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Atezolizumab
e. Bevacizumab
f. Eribulin
g. Everolimus + Exemestane
h. Fulvestrant as a single agent
i. Gemcitabine + Paclitaxel
j. Lapatinib
k. Neratinib
l. Olaparib
m. Palbociclib + Anastrozole/Exemestane/Letrozole
n. Palbociclib + Fulvestrant
o. Pertuzumab + Trastuzumab + Docetaxel
p. Ribociclib + Anastrozole/Exemestane/Letrozole
q. Ribociclib + Fulvestrant
r. Talazoparib
s. Transtuzumab + Paclitaxel
t. Transtuzumab as a single agent
u. Trastuzumab emtansine
v. Any other active systemic anti-cancer therapy

Download response Melanoma and breast cancer. 20.10.20